ID   HCC2185
AC   CVCL_3375
SY   HCC-2185; HCC 2185
DR   EFO; EFO_0001178
DR   ArrayExpress; E-TABM-157
DR   ATCC; CRL-2342
DR   BioSample; SAMN03472913
DR   Cosmic; 1136368
DR   DepMap; ACH-002322
DR   GEO; GSM350519
DR   GEO; GSM1053696
DR   GEO; GSM1172964
DR   KCLB; 9S2185
DR   LINCS_HMS; 51093
DR   LINCS_LDP; LCL-2074
DR   PharmacoDB; HCC2185_489_2019
DR   Wikidata; Q54881636
RX   PubMed=9833771;
RX   PubMed=11314036;
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=20679594;
RX   PubMed=21778573;
RX   PubMed=24094812;
RX   PubMed=24176112;
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: GrayJW Breast Cancer Cell Line Panel.
CC   Doubling time: 163.56 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Discontinued: ATCC; CRL-2342; true.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): PubMed=20679594; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 8,10
ST   D13S317: 12
ST   D16S539: 10
ST   D18S51: 15
ST   D19S433: 13
ST   D21S11: 32.2
ST   D2S1338: 20
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 12,13
ST   D8S1179: 14
ST   FGA: 23
ST   Penta D: 11
ST   Penta E: 10
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 18,19
DI   NCIt; C76328; Metastatic lobular breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 20
//
RX   PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L;
RA   Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L., Sakaguchi M.,
RA   Westerfield M., Kodagoda D., Stasny V., Cunningham H.T., Wistuba I.I.,
RA   Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.;
RT   "Characterization of paired tumor and non-tumor cell lines established
RT   from patients with breast cancer.";
RL   Int. J. Cancer 78:766-774(1998).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//